BR112017007102A2 - uso de um medicamento no tratamento de patologias da córnea, composição oftálmica para uso de um medicamento no tratamento de doenças da córnea e método para preparar a composição oftálmica - Google Patents

uso de um medicamento no tratamento de patologias da córnea, composição oftálmica para uso de um medicamento no tratamento de doenças da córnea e método para preparar a composição oftálmica

Info

Publication number
BR112017007102A2
BR112017007102A2 BR112017007102A BR112017007102A BR112017007102A2 BR 112017007102 A2 BR112017007102 A2 BR 112017007102A2 BR 112017007102 A BR112017007102 A BR 112017007102A BR 112017007102 A BR112017007102 A BR 112017007102A BR 112017007102 A2 BR112017007102 A2 BR 112017007102A2
Authority
BR
Brazil
Prior art keywords
treatment
medicament
ophthalmic composition
corneal disorders
preparing
Prior art date
Application number
BR112017007102A
Other languages
English (en)
Other versions
BR112017007102B1 (pt
Inventor
Raspollini Elisabetta
Rebulla Paolo
Villa Stefania
Original Assignee
Fond Irccs Ca Granda Ospedale Maggiore Policlinico
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fond Irccs Ca Granda Ospedale Maggiore Policlinico filed Critical Fond Irccs Ca Granda Ospedale Maggiore Policlinico
Publication of BR112017007102A2 publication Critical patent/BR112017007102A2/pt
Publication of BR112017007102B1 publication Critical patent/BR112017007102B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)

Abstract

a presente invenção refere-se a novas preparações oftálmicas para o tratamento de patologias da córnea compreendendo o plasma sanguíneo do cordão umbilical.
BR112017007102-9A 2014-10-06 2015-10-06 Uso de uma composição oftálmica, composição oftálmica e método para preparar a composição oftálmica BR112017007102B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2014A001745 2014-10-06
ITMI20141745 2014-10-06
PCT/EP2015/073031 WO2016055464A1 (en) 2014-10-06 2015-10-06 Ophthalmic compositions

Publications (2)

Publication Number Publication Date
BR112017007102A2 true BR112017007102A2 (pt) 2018-01-23
BR112017007102B1 BR112017007102B1 (pt) 2021-10-19

Family

ID=51753350

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017007102-9A BR112017007102B1 (pt) 2014-10-06 2015-10-06 Uso de uma composição oftálmica, composição oftálmica e método para preparar a composição oftálmica

Country Status (8)

Country Link
US (2) US20170246218A1 (pt)
EP (1) EP3204023A1 (pt)
JP (1) JP2017534605A (pt)
BR (1) BR112017007102B1 (pt)
CA (1) CA2963435A1 (pt)
IL (1) IL251590B (pt)
RU (1) RU2768494C2 (pt)
WO (1) WO2016055464A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110604811B (zh) * 2018-06-14 2023-01-31 陕西慧康生物科技有限责任公司 含有重组人溶菌酶和重组人表皮生长因子的人工泪液

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011145110A1 (en) * 2010-05-15 2011-11-24 Subhadra Dravida A novel cord blood plasma nutrient formulation and a method for the preparation thereof
WO2011150375A2 (en) * 2010-05-28 2011-12-01 Indiana University Research And Technology Corporation Endothelial colony forming cell culture medium

Also Published As

Publication number Publication date
CA2963435A1 (en) 2016-04-14
RU2017115859A3 (pt) 2019-05-15
IL251590A0 (en) 2017-06-29
US20220079997A1 (en) 2022-03-17
RU2017115859A (ru) 2018-11-13
WO2016055464A1 (en) 2016-04-14
JP2017534605A (ja) 2017-11-24
WO2016055464A8 (en) 2016-06-23
BR112017007102B1 (pt) 2021-10-19
RU2768494C2 (ru) 2022-03-24
EP3204023A1 (en) 2017-08-16
US20170246218A1 (en) 2017-08-31
IL251590B (en) 2021-02-28

Similar Documents

Publication Publication Date Title
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
EA201691582A1 (ru) Новые фармацевтические препараты
BR112017001796A2 (pt) composições de flagelina e seus usos
BR112017004893A2 (pt) composições e métodos para o tratamento de lesões cutâneas pré-cancerosas
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX355853B (es) Composicion oftalmica para el tratamiento de infeccion ocular.
ZA201703467B (en) Methods of treating ocular conditions
IT201600103956A1 (it) Formulazione oftalmica comprendente citicolina veicolata da liposomi per il trattamento del glaucoma
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2017009608A (es) Compuestos anticancerigenos.
BR112017009358A2 (pt) imunoterapia específica de peptídeo t terapêutico para uso no tratamento de metástase cerebral de um paciente com hla-2 positivo
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний
BR112018009540A2 (pt) derivados de diamino piridina
BR112017007095A2 (pt) conjugados e derivados de prostaglandina para tratamento de glaucoma e hipertensão ocular
EA201700254A1 (ru) Комбинация
BR112017007102A2 (pt) uso de um medicamento no tratamento de patologias da córnea, composição oftálmica para uso de um medicamento no tratamento de doenças da córnea e método para preparar a composição oftálmica
TR201819920T4 (tr) Kuru göz sendromunun tedavisinde kullanım için oftalmik bileşimler.
EP3238723A4 (en) Drug for treating disorders of corneal epithelium
EA201692164A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом
BR112017012931A2 (pt) métodos para redução de agregação plaquetária e tratamento de doença cardiovascular e outros distúrbios médicos
EP3170500A4 (en) Prophylactic or therapeutic agent for diseases of posterior segment of eye
BR112016029044A2 (pt) ácido 2-(2-metilamino-pirimidin-4-il)-1h-indol-5-carboxílico [(s)-1-carbamoil-2-(fenil-pirimi¬din-2-il-amino)-etil]-amida para utilização no tratamento de dor associada à osteoartrite
GR1008527B (el) Οφθαλμικο φαρμακευτικο σκευασμα ελευθερο συντηρητικου περιεχον βιματοπροστη

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/10/2015, OBSERVADAS AS CONDICOES LEGAIS.